[The effect of long-term Enduracin monotherapy on the clinical and biochemical status of patients with ischemic heart disease].
13 patients aged 39 to 60 years with coronary atherosclerosis confirmed at selective coronary angiography combined with primary hyperlipidemia (phenotypes 2a and 2b) received enduracin in a dose 1500 mg/day. As a result of the treatment total cholesterol (TC) and LDL cholesterol lowered by 10.3 and 13.1%, respectively, whereas HDL cholesterol rose by 15.2%. Half of the patients demonstrated activation of hepatic transaminases, but discontinuation of the drug was not necessary. In 3 out of 4 patients after 2 years of enduracin treatment stabilization of atherosclerosis was observed. Thus, long-term enduracin is able to inhibit progression of atherosclerosis in coronary heart disease patients.
Kukharchuk
V V
VV
Solov'ev
E Iu
EIu
Malyshev
P P
PP
Rozhkova
T A
TA
Semenova
O A
OA
Aronskaia
E E
EE
D000328:Adult; D002319:Cardiovascular System / Q000187:drug effects; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004064:Digestive System / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy*; D009525:Niacin / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D003692:Delayed-Action Preparations; D000960:Hypolipidemic Agents; D009525:Niacin